We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Bispecific Antibodies: A New Frontier in the Care of Patients With Refractory Multiple Myeloma
Sagar Lonial, MD, FACP
Caitlin Costello, MD
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Charu Aggarwal, MD, MPH
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Alexander Drilon, MD
Approved Bispecific Antibodies for RRMM: Review of the Pivotal Trials
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Preventing CRS and Neurotoxicities Related to Bispecific Antibodies
Managing Infections, Cytopenias, and Other AEs Related to Bispecific Antibodies
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Efficacy Data for Bispecific Antibodies in RRMM
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Step-Up Dosing of Bispecific Antibodies: The Need for Hospitalization
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach Into Current and Emerging Management
Kristen Ciombor, MD
James J. Harding, MD
Filippo Pietrantonio, MD
Kanwal Raghav, MD
Navigating Challenges in Metastatic Gastric/GEJ Cancer Management: Advancements in Biomarker-Directed Therapies
Yelena Janjigian, MD
Samuel J. Klempner, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education